Drug Type Small molecule drug |
Synonyms OPB111077, OPB 111077, OPC-317 |
Target |
Action inhibitors |
Mechanism STAT3 inhibitors(Signal transducer and activator of transcription 3 inhibitors), Mitochondrial oxidative phosphorylation inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | Singapore | 22 May 2017 | |
Diffuse large B-cell lymphoma recurrent | Phase 1 | Japan | 22 Nov 2019 | |
Diffuse large B-cell lymphoma refractory | Phase 1 | Japan | 22 Nov 2019 | |
Refractory acute myeloid leukemia | Phase 1 | United States | 17 Mar 2017 | |
Relapsing acute myeloid leukemia | Phase 1 | United States | 17 Mar 2017 | |
Advanced Hepatocellular Carcinoma | Phase 1 | South Korea | 29 May 2013 | |
Advanced cancer | Phase 1 | United States | 01 Jun 2012 | |
Solid tumor | Phase 1 | United States | 01 Jun 2012 |
Phase 1 | 16 | OPB-111077 400 mg + Bendamustine 120 mg/m2 | truxevgync(xgojabcafw) = dshtsdccuy yobdypzqqy (jbhhanhcrj ) | - | 11 Dec 2023 | ||
Phase 1 | Refractory acute myeloid leukemia First line | - | sqniuplynu(khvqemkuyz) = febrile neutropenia 56% yhqqhryifh (fqpzbyrtck ) View more | Positive | 05 Nov 2020 | ||
NCT01942083 (Pubmed) Manual | Phase 1 | 33 | (continuous dosing) | vuzdznztnw(jbuefikoha) = ftdvxrmcon gkyjilmigp (dtdteecfod ) | Negative | 01 Apr 2019 | |
(intermittent dosing) | vuzdznztnw(jbuefikoha) = wwaawwbpws gkyjilmigp (dtdteecfod ) | ||||||
NCT01711034 (Pubmed) Manual | Phase 1 | 145 | zvefmdgwwn(zmsaapajbj) = TEAEs were generally mild to moderate and could be medically managed. yivkmirndr (eqiafilqwj ) | Positive | 01 Jun 2018 |